Literature DB >> 16809213

An open label pilot investigation of the efficacy of Botulinum toxin type A [Dysport] injection in the rehabilitation of chronic anterior knee pain.

B J Singer1, P L Silbert, J W Dunne, S Song, K P Singer.   

Abstract

PURPOSE: To examine the effect of intramuscular injection of botulinum toxin type A [Dysport] to reduce relative overactivity of the vastus lateralis [VL] muscle, in conjunction with re-training of vastus medialis [VM] muscle as an adjunct to rehabilitation for chronic anterior knee pain.
METHOD: Eight females with chronic (>6 months) history of anterior knee pain, who had failed conservative management, were studied in this open label pilot study. Intramuscular Dysport injection [300 - 500 units] to the distal third of VL muscle was followed by a 12-week customized home exercise programme to improve recruitment of VM muscle and functional knee control. VL and VM muscle cross sectional area from a standardized spiral CT sequence, isometric quadriceps strength (dynamometry), timed stair task, self-reported pain and disability were assessed.
RESULTS: Subjects reported reduced knee pain and brace dependency and increased participation in sporting and daily living activities. Isometric quadriceps muscle strength was maintained or improved despite significant atrophy, evident on CT, of the distal component of VL in the treated limb. Time taken to ascend and descend a flight of stairs improved in all subjects. Subjective and objective improvements were maintained at 24-week follow-up.
CONCLUSIONS: These pilot data provide preliminary support for the role of Dysport as an adjunct to non-surgical management of individuals with chronic anterior knee pain. Larger double blind, randomized, placebo-injection controlled studies of this novel approach to improving patellofemoral mechanics are needed to establish the efficacy of this intervention.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16809213     DOI: 10.1080/09638280500301477

Source DB:  PubMed          Journal:  Disabil Rehabil        ISSN: 0963-8288            Impact factor:   3.033


  8 in total

Review 1.  Botulinum toxin for pain.

Authors:  Roberto Casale; Valeria Tugnoli
Journal:  Drugs R D       Date:  2008

2.  Botulinum toxin therapy for osteoarticular pain: an evidence-based review.

Authors:  Jasvinder A Singh
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-04-01       Impact factor: 5.346

3.  Treatment of refractory anterior knee pain using botulinum toxin type A (Dysport) injection to the distal vastus lateralis muscle: a randomised placebo controlled crossover trial.

Authors:  Barbara J Singer; Peter L Silbert; Swithin Song; John W Dunne; Kevin P Singer
Journal:  Br J Sports Med       Date:  2010-04-23       Impact factor: 13.800

Review 4.  Use of botulinum toxin in musculoskeletal pain.

Authors:  Jasvinder A Singh
Journal:  F1000Res       Date:  2013-02-15

Review 5.  Research Methods and Progress of Patellofemoral Joint Kinematics: A Review.

Authors:  Zhenguo Yu; Jie Yao; Xingliang Wang; Xing Xin; Ke Zhang; Hong Cai; Yubo Fan; Bin Yang
Journal:  J Healthc Eng       Date:  2019-03-24       Impact factor: 2.682

6.  Botulinum toxin injections as salvage therapy is beneficial for management of patellofemoral pain syndrome.

Authors:  Yuval Kesary; Vivek Singh; Tal Frenkel-Rutenberg; Arie Greenberg; Shmuel Dekel; Ran Schwarzkopf; Nimrod Snir
Journal:  Knee Surg Relat Res       Date:  2021-10-29

7.  High Precision Use of Botulinum Toxin Type A (BONT-A) in Aesthetics Based on Muscle Atrophy, Is Muscular Architecture Reprogramming a Possibility? A Systematic Review of Literature on Muscle Atrophy after BoNT-A Injections.

Authors:  Alexander D Nassif; Ricardo F Boggio; Sheila Espicalsky; Gladstone E L Faria
Journal:  Toxins (Basel)       Date:  2022-01-21       Impact factor: 4.546

Review 8.  The Role of Botulinum Toxin Type A in the Clinical Management of Refractory Anterior Knee Pain.

Authors:  Barbara J Singer; Benjamin I Silbert; Peter L Silbert; Kevin P Singer
Journal:  Toxins (Basel)       Date:  2015-08-25       Impact factor: 4.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.